Hussein Assi, MD | Boston Medical Center

Dr. Hussein Assi

Claim this profile

Boston Medical Center

Studies Gastric Cancer
Studies Uterine Tumors
6 reported clinical trials
14 drugs studied

Area of expertise

1Gastric Cancer
Hussein Assi has run 3 trials for Gastric Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative
2Uterine Tumors
Hussein Assi has run 3 trials for Uterine Tumors. Some of their research focus areas include:
Stage IV
HER2 negative
KRAS positive

Affiliated Hospitals

Image of trial facility.
Boston Medical Center

Clinical Trials Hussein Assi is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

RYZ101

for Neuroendocrine Tumors

This trial tests RYZ101, a new drug, in patients with advanced GEP-NETs that haven't responded to previous treatments. The drug aims to target specific receptors on the tumor cells to stop their growth.
Recruiting2 awards Phase 312 criteria

More about Hussein Assi

Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Hussein Assi has experience with
  • Nivolumab
  • RYZ101
  • Carboplatin
  • Ipilimumab
  • Paclitaxel
  • Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Hussein Assi specialize in?
Is Hussein Assi currently recruiting for clinical trials?
Are there any treatments that Hussein Assi has studied deeply?
What is the best way to schedule an appointment with Hussein Assi?
What is the office address of Hussein Assi?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security